The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC

Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Marwitz, Sebastian, Turkowski, Kati, Nitschkowski, Dörte, Weigert, Andreas, Brandenburg, Julius, Reiling, Norbert, Thomas, Michael, Reck, Martin, Drömann, Daniel, Seeger, Werner, Rabe, Klaus F., Savai, Rajkumar, Goldmann, Torsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985561/
https://www.ncbi.nlm.nih.gov/pubmed/32039023
http://dx.doi.org/10.3389/fonc.2019.01550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985561/
https://www.ncbi.nlm.nih.gov/pubmed/32039023
http://dx.doi.org/10.3389/fonc.2019.01550

Ejemplares similares